Exposure and safety
Treatment‐relatedness, Cancer
ADVERSE EVENT, ADVERSE EVENTS, ADVERSE EVENT, EVENTS, CANCER
Among all treated Chinese patients, the median (range) duration of treatment in the nivolumab plus chemotherapy group was 6.3 months (0.1‐32.6) for patients receiving nivolumab plus XELOX and 6.5 months (1.0‐30.0) for patients receiving nivolumab plus FOLFOX, while the median duration of treatment was 4.0 months (0.0‐29.2) and 3.9 months (0.8‐30.3) for patients receiving XELOX or FOLFOX alone, respectively. The duration of chemotherapy treatment was similar when comparing nivolumab plus chemotherapy to chemotherapy with the same backbone (Supplementary Table Summary of treatment‐related adverse events in all patients
Patients who received at least one dose of study drug. Includes events reported between first dose and 30 days after last dose of trial therapy. Treatment‐relatedness in the nivolumab plus chemotherapy group refers to nivolumab at least one chemotherapy component or both. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 and Medical Dictionary for Regulatory Activities version 23.0. There were no grade 5 events in either treatment group.